Product image of Nimodipine Altan (Nimodipine) supplied by GNH India

Nimodipine Altan

Active Ingredient:
Nimodipine
Origin:
EU

Nimodipine Altan (Nimodipine)

Nimodipine, the active ingredient in Nimodipine Altan, is a calcium channel blocker presented as an intravenous solution for intravenous use. It is employed to prevent cerebral vasospasm following subarachnoid hemorrhage, helping to maintain adequate cerebral blood flow in affected patients.

GNH India supplies Nimodipine Altan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Manufacturer / TM Owner

Altan Pharmaceuticals S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Nimodipine is used in the management of cerebrovascular complications, particularly those related to subarachnoid hemorrhage.
  • Aneurysmal subarachnoid hemorrhage: prevents delayed cerebral vasospasm and reduces risk of ischemic complications.
  • Delayed cerebral ischemia after SAH: lowers incidence of secondary brain injury.
  • Cerebral blood flow impairment post‑SAH: supports perfusion to vulnerable brain tissue.

How It Works

  • Nimodipine selectively antagonizes L‑type calcium channels on vascular smooth‑muscle and neuronal cells, decreasing calcium influx. This action produces pronounced cerebral vasodilation, improves microvascular blood flow, and confers neuroprotective effects by limiting calcium‑mediated neuronal injury during ischemic events.

Side Effects

Nimodipine may be associated with several adverse reactions, which are categorized by frequency.

Common Side Effects

  • Hypotension: reduced blood pressure, especially after rapid infusion.
  • Headache: mild to moderate intensity.
  • Nausea: occasional gastrointestinal upset.
  • Flushing: transient warmth and redness of skin.
  • Dizziness: sensation of light‑headedness.
  • Tachycardia: increased heart rate.

Serious or Rare Side Effects

  • Severe hypotension: marked drop in blood pressure requiring intervention.
  • Myocardial infarction: rare cardiac ischemic events.
  • Arrhythmias: abnormal heart rhythms, including bradycardia.
  • Hepatic dysfunction: elevated liver enzymes.
  • Allergic reactions: rash, pruritus, or anaphylaxis.
  • Seizures: infrequent neurologic events.

Precautions & Warnings

  • When prescribing Nimodipine, clinicians should consider several precautionary measures to ensure safe use.
  • Blood pressure monitoring: check for hypotension before and during therapy.
  • Cardiac function assessment: evaluate for existing heart block or ischemia.
  • Liver function: monitor enzymes in patients with hepatic impairment.
  • Concomitant vasodilators: avoid additive hypotensive effects.
  • Pregnancy and lactation: use only if benefits outweigh risks.
  • Store below 25°C: keep in the original pack, protect from moisture and light.

Avoid Interactions

Nimodipine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels leading to toxicity.
  • Potent vasodilators (e.g., nitroglycerin): risk of severe hypotension.
  • Beta‑blockers: may exacerbate bradycardia and hypotension.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness.
  • Diuretics: may enhance hypotensive effect.
  • Antihypertensive agents: dose adjustment may be required.

Frequently Asked Questions

Nimodipine Altan is indicated to prevent cerebral vasospasm following subarachnoid hemorrhage, helping to maintain adequate blood flow to the brain and reduce the risk of delayed ischemic neurological deficits.

Nimodipine blocks L‑type calcium channels on vascular smooth‑muscle and neuronal cells, reducing calcium entry. This causes selective dilation of cerebral arteries, improves microcirculation, and provides neuroprotective effects by limiting calcium‑mediated neuronal injury.

The dosage and infusion rate of Nimodipine Altan are determined by the prescribing clinician based on the patient’s clinical condition, weight, and response. Exact regimens are not disclosed here and should follow the prescriber’s order.

Safety data in pregnancy and lactation are limited. Nimodipine should only be used when the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Nimodipine is a calcium‑channel blocker specifically approved for cerebral vasospasm after subarachnoid hemorrhage, whereas other agents such as clazosentan or endothelin antagonists target similar pathways but have different efficacy and safety profiles. Nimodipine’s selective cerebral vasodilation and neuroprotective properties make it a standard first‑line option.

Store the product below 25 °C in its original packaging, protecting it from moisture and direct light. Do not freeze. Follow any additional handling instructions provided with the shipment to maintain product integrity.

Nimodipine Altan is given intravenously under the supervision of qualified healthcare professionals. The infusion is typically administered via a controlled IV pump, with vital signs monitored throughout the procedure.

Serious risks include severe hypotension, myocardial infarction, life‑threatening arrhythmias, hepatic dysfunction, and rare allergic reactions such as anaphylaxis. Prompt recognition and management of these events are essential.

Patients with known hypersensitivity to nimodipine or any component of the formulation, those with uncontrolled severe hypotension, significant cardiac conduction abnormalities, or severe hepatic impairment should avoid using Nimodipine Altan unless a physician determines that benefits outweigh risks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Nimodipine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT